You are here:

Archived: Buprenorphine transdermal patches (BuTrans)

Advice

Following a full submission

Buprenorphine transdermal patch (BuTrans) is not recommended for use within NHS Scotland for the treatment of severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics. There was a lack of evidence of comparative efficacy with a clinically relevant treatment for chronic pain available in the UK.

The economic case has not been demonstrated. The licence holder has indicated their decision to resubmit.

Drug Details

Drug Name: Buprenorphine transdermal patches (BuTrans)
SMC Drug ID: 234/06
Manufacturer: Napp Pharmaceuticals Ltd
Indication: Severe opioid responsive pain conditions which are not adequately responding to non-opioid analgesics
BNF Category:
Sub Category: 4.7 Analgesics
Submission Type: Full submission
Status: Not Recommended
Date Advice Published: 13 February 2006

Current Advice

Resubmission 12 January 2009

Archived Advice

Resubmission 11 August 2008
Resubmission 7 May 2007

Back